Presenting at AHS 2022, researchers assessed the efficacy of a 1-year treatment period with ubrogepant 50 or 100 mg in patients with migraine attacks with mild and moderate or severe pain.
Researchers examined meaningful within-patient changes in WOMAC using data from 3 trials that included patients with moderate to severe hip and knee osteoarthritis.
Among patients with hand osteoarthritis, higher BMI is associated with greater pain severity in hands, feet, knees, and hips.
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
There was a decrease in nonpharmacologic therapy and an increase in opioid prescription during the COVID-19 pandemic versus 2019.
Unintentional opioid deaths from July 2017 to June 2020, the pre and post Covid-19 era, are described by key decedent and death scene characteristics.
Researchers sought to explore how inpatients understand and utilize the Verbal Rating Scale in a hospital setting.
Researchers conducted a study to assess the effect of galcanezumab on the total pain burden of patients with episodic cluster headache.
Study researchers conducted a narrative review to update the public on the new classification of trigeminal neuralgia, clinical signs, pathophysiology, and management.
Researchers presented a study protocol for a trial evaluating the efficacy of 3 forms of virtual reality interventions for patients with highly prevalent chronic lower back pain.
